ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

MAZE vs NVAX // RSI-14 & 200D SMA MOMENTUM

Maze Therapeutics Inc. (NASDAQ) VS. Novavax Inc. (NASDAQ) • 15-METRIC TALLY: MAZE 3 — NVAX 2
▲ RSI-14 & 200D SMA MOMENTUM LEADER: MAZE
rsi-technicals
63.3
rsi-technicals
44.9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MAZE VS. NVAX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC MAZE NVAX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 93.50% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 85.00% -120.00 NVAX /roic <GO>
EV/EBITDA & P/E Valuation — 3.3x — TIE /valuation <GO>
Free Cash Flow Yield -6.36% -14.17% +7.81 MAZE /fcf-yield <GO>
Operating Margin — 40.30% — TIE /operating-margins <GO>
Net Profit Margin — 39.20% — TIE /net-margins <GO>
Revenue Growth (YoY) — 64.70% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 5/9 -3.00 NVAX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 63.3 44.9 +18.37 MAZE /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 3.5x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.77B $1.73B $46.7M MAZE /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR MAZE REV NVAX REV MAZE GROSS % NVAX GROSS % MAZE FCF NVAX FCF
FY 2025 $0 $1.12B — 93.5% -$112.7M -$244.6M
FY 2024 $167.5M $682.2M — 70.3% $74.8M -$87.3M
FY 2023 — $983.7M — — — -$714.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MAZE // BETA —
NVAX // BETA —